|
 |
European Pharmaceutical Contractor
|
Naturally occurring infectious diseases are a devastating phenomenon. Today, however, there is a new threat: infectious diseases could be used intentionally as weapons of bioterrorism. Advances in science and information dissemination have meant that developing infectious diseases in this way may also not be restricted to nation states alone. Biological weapons can be developed and used by a wide range of groups. As Steve Bowman, a specialist in national defence, stated in a report to US Congress, "Worldwide, the likelihood of terrorists being capable of producing or obtaining weapons of mass destruction may be growing due to looser controls of stockpiles and technology in the former Soviet states specifically, and the broader dissemination of related technology and information in general (1)". In the report, he goes on to discuss concerns about the 'clear trend among terrorists to inflict greater numbers of casualties.'
Governments around the world are taking steps to protect their populations against this threat. One starting point is vaccines, as these are recognised as one of the most effective ways to protect people from infectious diseases.
Smallpox - A Case Study
Smallpox was one of the most devastating diseases known to mankind. Over the centuries, it has killed more people than any other infectious disease, including 300 million in the last Century. Regular vaccination programmes throughout developed countries in the middle decades of the 20th Century meant that, by the 1960s, smallpox was persistently circulating only within specific areas of the world. This enabled the World Health Organization (WHO) to launch a worldwide campaign to eradicate smallpox by vaccination in 1967.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
